

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)							
1. Name and Address of Reporting Person [*] 2. Date of Event Pepose Jay Statement (Monthematical State			3. Issuer Name and Ticker or Trading Symbol Ocuphire Pharma, Inc. [OCUP]				
(Last) (First) (Middle) 37000 GRAND RIVER AVE, SUITE 120	06/07/2021		Issuer	f Reporting Person	· · /	5. If Amendment, Date Original Filed(Month/Day/Year)	
(Street) FARMINGTON HILLS, MI 48335			(Check _X_Director Officer (give ti below)	c all applicable) theOther (specify below)		6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned						
		Amount of Securities eneficially Owned nstr. 4)		1	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock	2,1	113		D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	Expiration Date		Securities Underlying Derivative Security		Price of		6. Nature of Indirect Beneficia Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	<u>(1)</u>	06/25/2029	Common Stock	4,226	\$ 1.15	D	
Stock Option (right to buy)	<u>(1)</u>	06/03/2030	Common Stock	10,565	\$ 1.65	D	
Stock Option (right to buy)	(2)	11/11/2030	Common Stock	30,000	\$ 4.05	D	

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Pepose Jay 37000 GRAND RIVER AVE SUITE 120 FARMINGTON HILLS, MI 48335	Х				

Signatures

06/09/2021 /s/ Emily J. Johns, by Power of Attorney **Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options are fully vested.

(2) 625 shares vesting on the last day of each month from November 2020 to October 2024 with the balance vesting in the last month, subject to the Reporting Person's continuing service through the vesting date.

Remarks:

Exhibit 24, Power of Attorney, is attached.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

EXHIBIT 24

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Mina Sooch, Bernhard Hoffmann, Amy Rabourn, Emily J. Johns, Hayley Johnson, and Stephanie Swan signing singly, his or her true and lawful attorney in fact to: 1. execute for and on behalf of the undersigned, with respect to the undersigneds position as a director and/or officer of Ocuphire Pharma, Inc. the Company, Form ID and Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16a of the Securities Exchange Act of 1934, as amended, and the rules thereunder; 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID or Forms 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange, stock market or similar authority; and 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of benefit to, and in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney in fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney in fact may approve in such attorney in facts discretion. The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in facts substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys in fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigneds responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigneds holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys in fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 31, 2021.

/s/ Jay Pepose